LY294002

For research use only.

Catalog No.S1105 Synonyms: SF 1101, NSC 697286

1280 publications

LY294002 Chemical Structure

CAS No. 154447-36-6

LY294002 (SF 1101, NSC 697286) is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family. LY294002 also inhibits CK2 with IC50 of 98 nM. LY294002 is a non-specific DNA-PKcs inhibitor and activates autophagy and apoptosis.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 191 In stock
USD 147 In stock
USD 270 In stock
USD 770 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's LY294002 has been cited by 1280 publications

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description LY294002 (SF 1101, NSC 697286) is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family. LY294002 also inhibits CK2 with IC50 of 98 nM. LY294002 is a non-specific DNA-PKcs inhibitor and activates autophagy and apoptosis.
Targets
CK2 [5]
(Cell-free assay)
p110α [1]
(Cell-free assay)
p110δ [1]
(Cell-free assay)
p110β [1]
(Cell-free assay)
DNA-PK [6]
(Cell-free)
98 nM 0.5 μM 0.57 μM 0.97 μM 1.4 μM
In vitro

LY294002 is not exclusively selective for the PI3Ks, and could in fact act on other lipid kinases and additional apparently unrelated proteins. LY294002 is shown to inhibit not only mTOR and DNA-PK, but also other protein kinases, such as CK2 (casein kinase 2) and Pim-1[5]. LY294002 inactivates Akt/PKB, consequently inhibiting cell proliferation and inducing apoptosis. LY294002 demonstrates a remarkable growth-inhibitory and apoptosis-inducing effect in these colon cancer cell lines, with decreased expression of phosphorylated Akt (Ser473). [2]LY294002 induces marked nuclear pyknosis and diminished cytoplasmic volume in the tumor cells. Thus, LY294002 markedly inhibits ovarian cancer cell proliferation in vitro. LY294002 induces specific G1 arrest in cell growth, leading to almost complete inhibition of melanoma cell proliferation and partial inhibition of MG-63 (osteosarcoma cell line) proliferation. The effect of LY294002 on cell cycle progression may provide insights into a possible link between the PI3K activation pathway and cancer cell cycle regulation. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Sf9 cells M3qzcGZ2dmO2aX;uJIF{e2G7 M3jUTGlvcGmkaYTpc44hd2ZiSHnzMZRi\2enZDDic5ZqdmViUFmzT{BmgHC{ZYPz[YQhcW5iU3[5JINmdGy|LDDJR|UxRTFyIN88UU4> NVnY[IdzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUC5PVg{PTFpPkGwPVk5OzVzPD;hQi=>
HeLa cells NUXQd2FQSmmwZHnu[{Bi\m[rbnn0fUBie3OjeR?= NInKOHpDcW6maX7nJIFn\mmwaYT5JIZweiCSSUOtb4lv[XOnIHnzc4xifGWmIH\yc40hUGWOYTDj[YxteyxiS3m9OkDPxE1? NWLLS4E3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUW2OVg5PzBpPkG1OlU5QDdyPD;hQi=>
HeLa cells NHrQZmVHfW6ldHnvckBie3OjeR?= NHriW5JKdmirYnn0bY9vKG:oIH3UU3IheHKxdHXpckBqe2:uYYTl[EBnem:vIFjlUIEh[2WubIOsJGlEPTB;Mj61JO69VS5? M4XpTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3NkW4PFcxLz5zNU[1PFg4ODxxYU6=
HeLa (human carcinoma) cells. NFLseZdHfW6ldHnvckBie3OjeR?= NV;2XXZIUW5idnn0do8hcW6qaXLpeIlwdiCxZjDEUmEu\GWyZX7k[Y51KHC{b4TlbY4hc2mwYYPlLGRPSS2SSzmg[pJwdSCKZVzhJEhpfW2jbjDjZZJkcW6xbXGpJINmdGy|LDDJR|UxRTFwNDFOwG0v MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPTZ3OEi3NEc,OTV4NUi4O|A9N2F-
human PC3 cells MXLQdo9tcW[ncnH0bY9vKGG|c3H5 NEHIbWMzPSEQvF2= MYSxNlAhcA>? MWnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFCFMzDj[YxteyCjdDCyOUB2VSCjZoTldkAyOjBiaILzJIJ6KE2WVDDhd5NigSC{ZXzheIl3\SC2bzDEUXNQ MkLhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ4OECxOVkoRjF4NkiwNVU6RC:jPh?=
human BJ cells NXvjUGJFTnWwY4Tpc44h[XO|YYm= NEH6em8zPSEQvF2= M2rQRlIhcA>? MnHSRYN1cX[jdHnvckBw\iCDa4SgdIhwe3Cqb4L5cIF1cW:wIHH0JHRpejNyODDpckBRTEeILYP0bY12dGG2ZXSgd4VzfW1ic4ThdpZm\CCqdX3hckBDUiClZXzsd{BifCB{NTD1UUB1emWjdHXkJFIhcHK|IHLl[o9z\SCSRFfGJINp[WyuZX7n[UBjgSCrbX31co9jdG:2dHnu[y=> M{\BXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4N{[3NFg2Lz5zNke2O|A5PTxxYU6=
human BJ cells M4nQUWZ2dmO2aX;uJIF{e2G7 MYqyOUDPxE1? MYmyJIg> MVnJcohq[mm2aX;uJI9nKFCLM1ugd4lodmGuaX7nJIlvKFCGR1[td5RqdXWuYYTl[EB{\XK3bTDzeIFzfmWmIHj1cYFvKEKMIHPlcIx{KHS{YX7z[oVkfGWmIIfpeIgheGyjc33p[EBGT0[SL2DIJIRwdWGrbjDv[kBCc3RiYYPz[ZN{\WRiYYOgd5VxeHKnc4Ppc44hd2ZiUFitSWdHWCC{ZXTpd5RzcWK3dHnvckB1dyCybHHzcYEhdWWvYoLhcoUh[XRiMkWgeW0hfHKnYYTl[EAzKGi{czDi[YZwemViUFTHSkBkcGGubHXu[4Uh[nliY3;u[o9k[WxibXnjdo9{[2:yeR?= NXvPe3JZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[3OlcxQDVpPkG2O|Y4ODh3PD;hQi=>
mouse mast cells NEP1OWdHfW6ldHnvckBie3OjeR?= NGXrR2MzOCEQvF2= NUO5Tpg{UW6qaXLpeIlwdiCxZjDTR2YucW6mdXPl[EBRU0JxQXv0JJBpd3OyaH;yfYxifGmxbjDpckBud3W|ZTDtZZN1KGOnbHzzJIF1KDJyIN88US=> MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjd6OUe0Nkc,OTZ5OEm3OFI9N2F-
THP1 cells NYD5S2wyTnWwY4Tpc44h[XO|YYm= MVXJcohq[mm2aX;uJI9nKE2FUEGtbY5lfWOnZDDjbIVud3SjeHnzJI9nKFSKUEGgZ4VtdHNuIFnDOVA:OzdizszNMi=> MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjd6OUe0Nkc,OTZ5OEm3OFI9N2F-
mouse Raw264 macrophage MWjGeY5kfGmxbjDhd5NigQ>? NF3qRotKdmirYnn0bY9vKG:oIFO1ZU1u\WSrYYTl[EBRU0JxQXv0JJBpd3OyaH;yfYxifGmxbjDpckBud3W|ZTDSZZczPjRibXHjdo9xcGGpZTygTWM2OD1zMDFOwG0v Mnr5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ5OEm3OFIoRjF4N{i5O|QzRC:jPh?=
THP1 cells NGLPR5FHfW6ldHnvckBie3OjeR?= M{XaT2lvcGmkaYTpc44hd2ZiTVPQNU1qdmS3Y3XkJHBMSi:Da4SgdIhwe3Cqb4L5cIF1cW:wIHnuJHRJWDFiY3XscJMtKEmFNUC9NU43PSEQvF2u MkLTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ5OEm3OFIoRjF4N{i5O|QzRC:jPh?=
THP1 cells NUDMOJEyTnWwY4Tpc44h[XO|YYm= NFO3PYRKdmirYnn0bY9vKG:oIGPDSlEucW6mdXPl[EBRU0JxQXv0JJBpd3OyaH;yfYxifGmxbjDpckBVUFBzIHPlcIx{NCCLQ{WwQVEvODFizszNMi=> MnnDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ5OEm3OFIoRjF4N{i5O|QzRC:jPh?=
human A375 cells M2DKZ3Bzd2yrZnXyZZRqd25iYYPzZZk> M1fJNVQ3KGh? NF;GSZhCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFGzO|Uh[2WubIOgZYZ1\XJiNE[gbJJ{NCCLQ{WwQVgvPCEQvF2u MkGxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTdyNEmyOFgoRjF5MES5NlQ5RC:jPh?=
HeLa cells MX3GeY5kfGmxbjDhd5NigQ>? NIHofGJKdmirYnn0bY9vKG:oIFHYMVc2ODNiYnnu[Ilv\yC2bzDy[YNwdWKrbnHueEBRdGt|IHX4dJJme3OnZDDpckBJ\UyjIHPlcIx{KGK7IGfld5Rmem5iYnzveEwhUUN3PUOg{txONg>? M3npflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5MUO1NlQ5Lz5zN{GzOVI1QDxxYU6=
human SW480 cells NIPWUXJHfW6ldHnvckBie3OjeR?= M3HhO|IxKM7:TR?= NYHiVplbOjRiaB?= MV;E[YNz\WG|ZTDpckB{fXK4aY\pckBmgHC{ZYPzbY9vKGmwIHj1cYFvKFOZNEiwJINmdGy|IHH0JFIxKHWPIHHmeIVzKDJ2IHjyd{BjgSCrbX31co9jdG:2IHHuZYx6e2m| NEfIO2U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{S3Nlk3Oid-MUe0O|I6PjJ:L3G+
human A375 cells NH3Z[mFRem:uaX\ldoF1cW:wIHHzd4F6 NVniU3NHUW6qaXLpeIlwdiCxZjDz[ZJ2dS2rbnT1Z4VlKHC{b3zp[oVz[XSrb36gc4YhcHWvYX6gRVM4PSClZXzsd{whUUN3ME24MlQh|ryPLh?= M1zlRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NkCxO|M6Lz5zN{[wNVc{QTxxYU6=
human A2780 cells Mnq1RZBweHSxc3nzJIF{e2G7 NUXmbFZzOiEQvF2= NWPr[I1HOTJiaB?= MVzJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHPpd5Bt[XSrbj3y[ZNqe3SjboSgbJVu[W5iQUK3PFAh[2WubIOgZZN{\XO|ZXSgZZMh\GWlcnXhd4UhcW5icHjvd5Bpd3K7bHH0[YQhSWu2IHzleoVtKGG2IEKgeW0h[W[2ZYKgNVIhcHK|IHL5JIludXWwb3Lsc5Qh[W6jbInzbZMv MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzZ6NECxPEc,OTd4OESwNVg9N2F-
human H4 cells MlXCSpVv[3Srb36gZZN{[Xl? Mo\ZNkBp MUnE[YNz\WG|ZTDpckBHYV[HLWLGVEshfmW|aXPs[UBqdnSnboPpeJkheGW{IHPlcIwhcW5iaIXtZY4hUDRiY3XscJMh[W[2ZYKgNkBpenNicnXsZZRqfmVidH:gZ49vfHKxbB?= NWLhemhNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUiwNlQ2QDRpPkG4NFI1PTh2PD;hQi=>
Sf9 cells MnrPSpVv[3Srb36gZZN{[Xl? MkTSTY5pcWKrdHnvckBw\iCFS{Kg[ZhxemW|c3XkJIlvKFOoOTDj[YxteyxiSVO1NF03NjlizszNMi=> NXP6cZFHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUizNlE4OTZpPkG4N|IyPzF4PD;hQi=>
rat RBL2H3 cells NU\UZ|JHTnWwY4Tpc44h[XO|YYm= NVzKcZdEUW6qaXLpeIlwdiCxZjDBNlMyQDdvaX7keYNm\CCmZXfyZY52dGG2aX;uJIlvKHKjdDDSRmwzUDNiY3XscJM> MkHrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh|Mki3NVYoRjF6M{K4O|E3RC:jPh?=
human U87MG cells MYfGeY5kfGmxbjDhd5NigQ>? MmXJTY5pcWKrdHnvckBw\iCJU1uzMYJmfGFiaX6gbJVu[W5iVUi3UWch[2WubIOgZpkhTUyLU1GsJGlEPTB;OD6xJO69VS5? NVfYS3dtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUizOFU3ODlpPkG4N|Q2PjB7PD;hQi=>
human H460 cells MVrGeY5kfGmxbjDhd5NigQ>? M2K3flMxKM7:TR?= NIK4R21KdmirYnn0bY9vKG:oIGDJN2shcW5iaIXtZY4hUDR4MDDj[YxteyCjc4Pld5Nm\CCjczDBb5QheGixc4Doc5J6dGG2aX;uJIF1KFOncjC0O|MhfXBidH:gN|AhfU1? Mk\lQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3MEG2NFEoRjF6NUCxOlAyRC:jPh?=
human U251HRE cells MXXGeY5kfGmxbjDhd5NigQ>? M{[yS2lvcGmkaYTpc44hd2ZiaInwc5hq[S2rbnT1Z4VlKEiLRkGgZYN1cX[jdHnvckBqdiCqdX3hckBWOjVzSGLFJINmdGy|IHL5JINmdGxiYnHz[YQhemWyb4L0[ZIh\2WwZTDhd5NigQ>? NUT2VI5DRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi1NFE3ODFpPkG4OVAyPjBzPD;hQi=>
human 184B5 cells MUPDfZRwfG:6aXRCpIF{e2G7 NYr2fZdoS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hOTh2QkWgZ4VtdHNiYomgV3JDKGG|c3H5MEBIUTVyPUO5MlM4KM7:TT6= NYDUUo1ZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi2PVE5QTRpPkG4OlkyQDl2PD;hQi=>
human MDA-MB-468 cells NYLxN21CS3m2b4TvfIlkyqCjc4PhfS=> M3TJOGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj20Olgh[2WubIOgZpkhW1KEIHHzd4F6NCCLQ{WwQVExNjRizszNMi=> NX\1Xlg5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi2PVE5QTRpPkG4OlkyQDl2PD;hQi=>
human MDA-MB-468 cells M1TzbWN6fG:2b4jpZ:Kh[XO|YYm= M2LpUmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj20Olgh[2WubIOgbY4heHKnc3XuZ4Uhd2ZiMUCgeW0h[2iub4LvdZVqdmViYomgV3JDKGG|c3H5MEBIUTVyPUiuNkDPxE1w NWTyfolWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi2PVE5QTRpPkG4OlkyQDl2PD;hQi=>
MDA-MB-231 cells NWDx[G5iS3m2b4TvfIlkyqCjc4PhfS=> M4KwVmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj2yN|Eh[2WubIOgZpkhW1KEIHHzd4F6NCCJSUWwQVYvPzFizszNMi=> MnrXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh4OUG4PVQoRjF6NkmxPFk1RC:jPh?=
human MDA-MB-468 cells MX3DfZRwfG:6aXRCpIF{e2G7 MV7DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvNE[4JINmdGy|IHnuJJBz\XOnbnPlJI9nKDJyIIXNJINpdG:{b4H1bY5mKGK7IGPSRkBie3Ojef-8kEBKSzVyPUSuO|Yh|ryPLh?= NVzMfFAzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi2PVE5QTRpPkG4OlkyQDl2PD;hQi=>
human MDA-MB-231 cells NYq3XINES3m2b4TvfIlkyqCjc4PhfS=> M1;BfmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj2yN|Eh[2WubIOgbY4heHKnc3XuZ4Uhd2ZiMUCgeW0h[2iub4LvdZVqdmViYomgV3JDKGG|c3H5MEBIUTVyPUSuN|Uh|ryPLh?= MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDZ7MUi5OEc,OTh4OUG4PVQ9N2F-
human MDA-MB-231 cells NX7TV2c3S3m2b4TvfIlkyqCjc4PhfS=> NFzOS5dEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOTEFvTVKtNlMyKGOnbHzzJIlvKHC{ZYPlcoNmKG:oIEKwJO69VSClaHzvdo9yfWmwZTDifUBUWkJiYYPzZZktKEeLPUOuN|Ih|ryPLh?= MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDZ7MUi5OEc,OTh4OUG4PVQ9N2F-
human MCF7 cells NF74[G9EgXSxdH;4bYPDqGG|c3H5 Mli2R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWNHPyClZXzsd{BjgSCVUlKgZZN{[XluIFfJQVMvOTZizszNMi=> NGrSRmI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOE[5NVg6PCd-MUi2PVE5QTR:L3G+
human MCF7 cells NXG3[G0yS3m2b4TvfIlkyqCjc4PhfS=> NXHkVpJpS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUOINzDj[YxteyCrbjDwdoV{\W6lZTDv[kAyOCC3TTDjbIxwem:zdXnu[UBjgSCVUlKgZZN{[XluIFfJOVA:Oy5yODFOwG0v M{K5[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NkmxPFk1Lz5zOE[5NVg6PDxxYU6=
human MCF7 cells MUPDfZRwfG:6aXRCpIF{e2G7 NHfnXmdEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOS0Z5IHPlcIx{KGmwIIDy[ZNmdmOnIH;mJFIxKM7:TTDjbIxwem:zdXnu[UBjgSCVUlKgZZN{[XluIFfJOVA:Oi54MzFOwG0v NELvfnM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOE[5NVg6PCd-MUi2PVE5QTR:L3G+
Sf21 cells M1T1dWZ2dmO2aX;uJIF{e2G7 M2LnemlvcGmkaYTpc44hd2ZibX;1d4UhemWlb33ibY5idnRiUFmzT4FteGijIHX4dJJme3OnZDDpckBj[WO3bH;2bZJ2ey2rbn\lZ5Rm\CCVZkKxJINmdGy|LDDJR|UxRTBwNTFOwG0v MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTd2OEK2PUc,OTl5NEiyOlk9N2F-
Sf9 cells M4rBbYZtfW:{ZYPj[Y51KHCxbHHybZpifGmxbjDhd5NigQ>? MUDJcohq[mm2aX;uJI9nKGi3bXHuJHBKO0upYX3tZUBmgHC{ZYPz[YQhcW5iU3[5JINmdGy|IHL5JIZtfW:{ZYPj[Y51KHCxbHHybZpifGmxbjDhd5NigQ>? NHv2VXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUGyNVY{OSd-MkGxNlE3OzF:L3G+
Sf9 cells NVvNSYNETmy3b4Lld4NmdnRicH;sZZJqgmG2aX;uJIF{e2G7 MXzJcohq[mm2aX;uJI9nKGi3bXHuJHBKO0ujbIDoZUBmgHC{ZYPz[YQhcW5iU3[5JINmdGy|IHL5JIZtfW:{ZYPj[Y51KHCxbHHybZpifGmxbjDhd5NigSxiSVO1NF0xNjV3IN88UU4> MonGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFzMkG2N|EoRjJzMUKxOlMyRC:jPh?=
human IGROV1 cells MYTGeY5kfGmxbjDhd5NigQ>? NEDHboIzPCCq M2DEWWNmdGxiY4njcIUh[XK{ZYP0JIlvKGi3bXHuJGlIWk:YMTDj[YxteyCjc4Pld5Nm\CCjczDhZ4N2dXWuYYTpc44h[XRiR{GgdIhie2ViYYSgOUBnd2ymIFnDOVAh[W[2ZYKgNlQhcHK|IHL5JIZtd3diY4n0c41mfHK7 MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTJzNkG1NUc,OjF{MU[xOVE9N2F-
human IGROV1 cells Mn;xSpVv[3Srb36gZZN{[Xl? M3rrTVI1KGh? NV;ETnl[S2WubDDjfYNt\SCjcoLld5QhcW5iaIXtZY4hUUeUT2[xJINmdGy|IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCjdDDHNUBxcGG|ZTDheEAyKG[xbHSgTWM2OCCjZoTldkAzPCCqcoOgZpkh\myxdzDjfZRwdWW2com= NWjNXnptRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGyNVYyPTFpPkKxNlE3OTVzPD;hQi=>
human IGROV1 cells M363OWZ2dmO2aX;uJIF{e2G7 NVyz[Xl7OjRxNEigbC=> M33rb2lvcGmkaYTpc44hd2ZiUFmzT{9Cc3RiaX6gbJVu[W5iSVfSU3YyKGOnbHzzJIF{e2W|c3XkJIF{KGSnY4LlZZNmKGmwIHP5Z4xqdiCGMTDs[ZZmdCCjdDCxJJRwKDVidHnt[ZMhUUN3MDDh[pRmeiB{NDD0c{A1QCCqcoOgZpkhX2W|dHXyckBjdG:2IHHuZYx6e2m| MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTJzNkG1NUc,OjF{MU[xOVE9N2F-
human IGROV1 cells NEn4dFJHfW6ldHnvckBie3OjeR?= NH;LTlMzPC92ODDo MliwTY5pcWKrdHnvckBw\iCSSUPLM2FsfCCrbjDoeY1idiCLR2LPWlEh[2WubIOgZZN{\XO|ZXSgZZMh\GWlcnXhd4UhcW5icHjvd5Bpd3K7bHH0[YQhSUuWIHzleoVtKGG2IEGgeI8hPSC2aX3ld{BKSzVyIHHmeIVzKDJ2IITvJFQ5KGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN? NHq2NZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUKxOlE2OSd-MkGyNVYyPTF:L3G+
human HCT116 cells NVzySWNHS3m2b4TvfIlkyqCjc4PhfS=> M4XCcVczKGh? NX:wT5FTS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEOWMUG2JINmdGy|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:PTZwMEGg{txONg>? MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl2NUK1NEc,OjF7NEWyOVA9N2F-
human KB cells NIjT[FlEgXSxdH;4bYPDqGG|c3H5 M1vIVFczKGh? MUjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDLRkBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTR2Lke2JO69VS5? NEnTUnA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUm0OVI2OCd-MkG5OFUzPTB:L3G+
HUVEC MXHGeY5kfGmxbjDhd5NigQ>? M3LVflExNTJ3IN88US=> NHnhXYY{OCCvaX6= M2nzbGlvcGmkaYTpc44hd2ZiVF7GZYxxcGFvc4TpcZVt[XSnZDDoeY1idiCLQ1HNMVEheHKxbX;0[ZIh[WO2aY\peJkh\XiycnXzd4VlKGmwIFjVWmVEKGG|c3Xzd4VlKGG|IHLleIEu\2GuYXP0c5Nq\GG|ZTDhZ5Rqfmm2eTDheEAyOCC2bzCyOUB2VSCycnX0doVifGWmIH\vdkA{OCCvaX7zJIJm\m:{ZTDUUmZidHCqYTDjbIFtdGWwZ3WgcYVie3W{ZXSgZYZ1\XJiNTDodpMh[nlibIXjbYZmemG|ZTDy[ZBwenSncjDn[Y5mKGG|c3H5 M17WOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MEK2OFExLz5{MkCyOlQyODxxYU6=
HUVEC M4faW2Z2dmO2aX;uJIF{e2G7 MWWxNE0zPSEQvF2= MX:xOkBp M3;WfmlvcGmkaYTpc44hd2ZiVF7GZYxxcGFvc4TpcZVt[XSnZDDJR2FONTFibWLORUBmgHC{ZYPzbY9vKGmwIFjVWmVEKGG2IEGwJJRwKDJ3IIXNJJBz\XS{ZXH0[YQh\m:{IEG2JIhzeyCkZX\vdoUhXE6IYXzwbIEh[2ijbHzlcodmKG2nYYP1doVlKGGodHXyJFYhcHK|IHL5JHJVNVCFUjDhcoFtgXOrcx?= Mnf3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJyMk[0NVAoRjJ{MEK2OFExRC:jPh?=
human HCT116 cells NXnxUZR1TnWwY4Tpc44h[XO|YYm= NY\zSXVFOTBizszN MofETY5pcWKrdHnvckBw\iCDa4Sg[ZhxemW|c3nvckBqdiCqdX3hckBJS1RzMU[gZ4VtdHNiYYSgNVAhfU1iYomgbY1ufW6xYnzveEBidmGueYPpdy=> Mle1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{MUK3NlEoRjJ{MkGyO|IyRC:jPh?=
human HCT116 cells MUnGeY5kfGmxbjDhd5NigQ>? Mk\NNVAh|ryP Mor1TY5pcWKrdHnvckBw\iCSSUPLZYxxcGFiSEGwOFdTKG23dHHueEBqdiCqdX3hckBJS1RzMU[gZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCDa4SgV4VzPDd|IIDoc5NxcG:{eXzheIlwdiCjdDCxNEB2VSCkeTDpcY12dm:kbH;0JIFv[Wy7c3nz M3\Qc|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MkGyO|IyLz5{MkKxNlczOTxxYU6=
human HCT116 cells Mn7mSpVv[3Srb36gZZN{[Xl? NWrkeYg3OTBizszN MXfJcohq[mm2aX;uJI9nKFCLM1vhcJBp[SCrbjDoeY1idiCKQ2SxNVYh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDBb5QhW2W{NEezJJBpd3OyaH;yfYxifGmxbjDheEAyOCC3TTDifUBqdW23bn;icI91KGGwYXz5d4l{ M4n6SVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MkGyO|IyLz5{MkKxNlczOTxxYU6=
human HCT116 cells NInRZVdHfW6ldHnvckBie3OjeR?= MkPoNVAh|ryP MV6xNEBucW5? MYLJcohq[mm2aX;uJI9nKFCLM1vhcJBp[SCKMUC0O3IhdXW2YX70JIlvKGi3bXHuJGhEXDFzNjDj[YxteyC3c3nu[{BcOzKSXVHUVEBifCBzMDD1UUBi\nSncjCxNEBucW6| M3r3VlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MkGyO|IyLz5{MkKxNlczOTxxYU6=
human HCT116 cells MY\GeY5kfGmxbjDhd5NigQ>? MX2xNEDPxE1? NXX2VnJSOTBibXnu MWfJcohq[mm2aX;uJI9nKFCLM1vhcJBp[SCrbjDoeY1idiCKQ2SxNVYh[2WubIOgeZNqdmdiW{OyVH1CXFBiYYSgNVAhfU1iYX\0[ZIhOTBibXnudy=> MoLSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{MUK3NlEoRjJ{MkGyO|IyRC:jPh?=
human HCT116 cells NV70b|lET3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVnwNpVwPDhiaB?= M2r1TWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGhEXDFzNjDj[YxteyCxdnXy[ZhxemW|c3nu[{BRUTONYXzwbIEh[W[2ZYKgOFghcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME22Mlch|ryPLh?= NIPsPIk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkKxNlczOSd-MkKyNVI4OjF:L3G+
human HCT116 cells MXLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mn3JOFghcA>? Ml7XS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gTGNVOTF4IHPlcIx{KGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZktKEmFNUC9OU45KM7:TT6= NEnLblE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkKxNlczOSd-MkKyNVI4OjF:L3G+
human HCT116 cells M3XSV2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M4\jVFQ5KGh? NFjsUHNIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBJS1RzMU[gZ4VtdHNib4\ldoV5eHKnc4PpcochWEl|S3HsdIhiKEhzMES3VkBufXSjboSgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OD13LkOg{txO M4KwZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MkGyO|IyLz5{MkKxNlczOTxxYU6=
human A549 cells Mn32R5l1d3SxeHnjxsBie3OjeR?= Mk\IO|IhcA>? MV\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYm= NETjS|k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkS4NFg2OSd-MkK0PFA5PTF:L3G+
human PC3 cells MkfOR5l1d3SxeHnjxsBie3OjeR?= MYK3NkBp MXvDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDQR|Mh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD14MT6zOUDPxE1w MmfmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2OEC4OVEoRjJ{NEiwPFUyRC:jPh?=
human HL60 cells MoGyR5l1d3SxeHnjxsBie3OjeR?= NITkcpg4OiCq MkH0R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGw3OCClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUmuPVQh|ryPLh?= NVvoeWo1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0PFA5PTFpPkKyOFgxQDVzPD;hQi=>
Sf21 cells MoC3SpVv[3Srb36gZZN{[Xl? NH\jOYZKdmirYnn0bY9vKG:oIH3veZNmKHerbHSgeJlx\SCSSUPLZYxxcGFiZYjwdoV{e2WmIHnuJHNnOjFiY3XscJMh[29vZYjwdoV{e2mwZzDOMZRmem2rbnHsJGhqey22YXfn[YQhcHWvYX6gdFg2[SC3c3nu[{BNNWGucHjhMZBpd3OyaHH0bYR6dGmwb4PpeI9tKHO3YoP0doF1\SCkeTDUUGMh[mG|ZXSgdIhwe3Cqb4KgbY1i\2mwZzygTWM2OD1yLkWg{txO MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjV{ME[zNEc,OjJ3MkC2N|A9N2F-
HEK293 cells NWXpNGZwTnWwY4Tpc44h[XO|YYm= M4DrNlEvPSCq MlPpSIl{eGyjY3Xt[Y51KG:oIGuzTH1NW0RiZoLvcUBpfW2jbjC1THQ3KHKnY3XweI9zKGW6cILld5Nm\CCrbjDISWszQTNiY3XscJMh[W[2ZYKgNU42KGi{czDifUBtcXG3aXSgd4NqdnSrbHzheIlwdiClb4XueIlv\w>? MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjV|N{G1N{c,OjJ3M{exOVM9N2F-
human H1299 cells MYLGeY5kfGmxbjDhd5NigQ>? NEnI[2QxNjFvM{Cg{txO MYGyOEBp M4O3Wmlv\HWldHnvckBw\iCMTlutcYVlcWG2ZXSgR2hQWCCneIDy[ZN{cW:wIHnuJIh2dWGwIFixNlk6KGOnbHzzJIF1KDBwMTD0c{A{OCC3TTDh[pRmeiB{NDDodpMh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz MmD4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ4MkKwOlkoRjJ{NkKyNFY6RC:jPh?=
human H1299 cells NYTVU5k{TnWwY4Tpc44h[XO|YYm= MUOwMlEuOzBizszN M3y2VlI1KGh? MX;JcoR2[3Srb36gc4YhTFJ3IHX4dJJme3Orb36gbY4hcHWvYX6gTFEzQTliY3XscJMh[XRiMD6xJJRwKDNyIIXNJIFnfGW{IEK0JIhzeyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM> M3;kd|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NkKyNFY6Lz5{Mk[yNlA3QTxxYU6=
human H1299 cells MmXGSpVv[3Srb36gZZN{[Xl? NIfxWlcxNjFvM{Cg{txO MnzDNlQhcA>? MoPWSI94diC{ZXf1cIF1cW:wIH;mJINKSVB{IHX4dJJme3Orb36gbY4hcHWvYX6gTFEzQTliY3XscJMh[XRiMD6xJJRwKDNyIIXNJIFnfGW{IEK0JIhzeyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZMhcW5icILld4Vv[2Vib3[gNVAxKHWpL33sJHRTSUmOIHHu[EBRUTONIHnubIljcXSxcjDMXVI6PDByMh?= NIrMcG09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mk[yNlA3QSd-MkK2NlIxPjl:L3G+
human H1299 cells M2DYUWZ2dmO2aX;uJIF{e2G7 NXWx[Wg3OC5zLUOwJO69VQ>? MV6yOEBp NVm2dHBSTG:5bjDy[Yd2dGG2aX;uJI9nKGOLQWCyJIV5eHKnc4Ppc44hcW5iaIXtZY4hUDF{OUmgZ4VtdHNiYYSgNE4yKHSxIEOwJJVOKGGodHXyJFI1KGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN? M1rScVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NkKyNFY6Lz5{Mk[yNlA3QTxxYU6=
MDA-MB-231 cells NYnycmtVS2WubDDpcpZie2mxbjDhd5NigQ>? NIS2XHQzPCCq MmLXTY5pcWKrdHnvckBw\iCncHn0bIVtcWGuIHfyc5d1cCCoYXP0c5IucW6mdXPl[EBk\WyuIH3p[5JifGmxbjDv[kBpfW2jbjDNSGEuVUJvMkOxJINmdGy|IIDy[U1qdmO3YnH0[YQh\m:{IEK0JIhzeyCkeTDj[YxtKGmwdnHzbY9vKGG|c3H5MEBKSzVyPUCuN|gh|ryPLh?= NF7kd4M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkiwOFExQCd-MkK4NFQyODh:L3G+
human LNCAP cells MlTySpVv[3Srb36gZZN{[Xl? M3rROVAvOS1|MDFOwG0> Ml3PNlQhcA>? NUHmTWdJTG:5boLl[5Vt[XSrb36gc4Yhe3W{dnn2bY4h\XiycnXzd4lwdiCrbjDoeY1idiCOTlPBVEBk\WyuczDheEAxNjFidH:gN|AhfU1iYX\0[ZIhOjRiaILzJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?= MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjh|MkOxOkc,OjJ6M{KzNVY9N2F-
human LNCAP cells M{DSeGZ2dmO2aX;uJIF{e2G7 M{L0NlAvOS1|MDFOwG0> NFrMNmw{OCCvaX6= NV\FWFQ3UW6qaXLpeIlwdiCxZjDBb5QheGixc4Doc5J6dGG2aX;uJIlvKGi3bXHuJGxPS0GSIHPlcIx{KGG2IECuNUB1dyB|MDD1UUBi\nSncjCzNEBucW6|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>? MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjh|MkOxOkc,OjJ6M{KzNVY9N2F-
human PC3 cells NFj2fWNHfW6ldHnvckBie3OjeR?= M2m4SVUxKM7:TR?= MWS4JIg> NW\aUYhvUW6mdXP0bY9vKG:oIICyNUBxem:2ZXnuJIV5eHKnc4Ppc44hcW5iaIXtZY4hWEN|IHPlcIx{KGG2IEWwJJVOKGmwY4XiZZRm\CCob4KgPEBpenNiYomgW4V{fGW{bjDicI91fGmwZzDy[YxifGm4ZTD0c{B2dnS{ZXH0[YQh[2:wdILvcC=> MmPlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ7OUi0O|IoRjJ{OUm4OFczRC:jPh?=
human BT474 cell MmjiVJJwdGmoZYLheIlwdiCjc4PhfS=> MYG3NkBp NEPoN5RKdmirYnn0bY9vKG:oIHj1cYFvKEKWNEe0JINmdGxicILvcIln\XKjdHnvckBi\nSncjC3NkBpenNiYomgd5Bm[3S{b4Doc5RwdWW2cnnjJIFv[Wy7c3nz89yNKEmFNUC9NlAvPyEQvF2u NX;FT|BwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0NVAxODVpPkKzOFExODB3PD;hQi=>
human PC3 cell M1fWdHBzd2yrZnXyZZRqd25iYYPzZZk> M2XXe|czKGh? MV3Jcohq[mm2aX;uJI9nKGi3bXHuJHBEOyClZXzsJJBzd2yrZnXyZZRqd25iYX\0[ZIhPzJiaILzJIJ6KHOyZXP0do9xcG:2b33leJJq[yCjbnHsfZNqeyxiSVO1NF0yOi5zIN88UU4> MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzRzMECwOUc,OjN2MUCwNFU9N2F-
human PC3 cells MkTMSpVv[3Srb36gZZN{[Xl? NXPpRXNPOzBibXnu NHfscFhKdmirYnn0bY9vKG:oIGDJN2shcW5iaIXtZY4hWEN|IHPlcIx{KGG|c3Xzd4VlKGG|IHTlZ5Jm[XOnIHnuJGFMXCCyaH;zdIhwenmuYYTpc44h[XRic3XybY5mKDR5MzDh[pRmeiB|MDDtbY5{KGK7IFXMTXNCNCCLQ{WwQVEvO87:TT6= MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzRzMECwOUc,OjN2MUCwNFU9N2F-
human MGC803 cells MYDGeY5kfGmxbjDhd5NigQ>? MYqyOUDPxE1? NX\pcYVDPDhiaB?= M{K0VGNmdGxiY4njcIUh[XK{ZYP0JIlvKGi3bXHuJG1ISzhyMzDj[YxteyCjc4Pld5Nm\CCjczDhZ4N2dXWuYYTpc44h[XRiR{KvUUBxcGG|ZTDheEAzPSC3TTDh[pRmeiB2ODDodpMhfXOrbnegdJJweGmmaYXtJIlw\GmmZTDzeIFqdmmwZzDh[pRmeiB2ODDodpMh[nliZnzve{BkgXSxbXX0[ZIhemWuYYTpeoUhfG9iY3;ueJJwdA>? NYPvZ5dtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxNVk5PjlpPkK0NVE6QDZ7PD;hQi=>
mouse RAW264.7 cells MlHxSpVv[3Srb36gZZN{[Xl? NUnDc4tYOjVizszN NWXKeJg3OjBiaB?= NUL0XXdDUW6qaXLpeIlwdiCxZjDQTVNMN0GNVDDpckBud3W|ZTDSRXczPjRwNzDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKEySUz3pcoR2[2WmIHnOU3MheHKxdHXpckBmgHC{ZYPzbY9vKGG2IEK1JO69VSCjZoTldkAzOCCqcoOgZpkhX2W|dHXyckBjdG:2IHHuZYx6e2m| MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ7OU[xOkc,OjR{OUm2NVY9N2F-
human A549 cells NFvWdopRem:uaX\ldoF1cW:wIHHzd4F6 MW[3NkBp NVPjNmw5SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gZYJ{d3KkYX7j[UBi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUiyMlMzKM7:TT6= NYrKUpdDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2PVM4QDdpPkK1Olk{Pzh5PD;hQi=>
human HuH7 cells M1TM[nBzd2yrZnXyZZRqd25iYYPzZZk> M4HXPVczKGh? MlThRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKdVi3JINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiYXLzc5Jj[W6lZTDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTZ5LkG4JO69VS5? NVTrZVZURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2PVM4QDdpPkK1Olk{Pzh5PD;hQi=>
human HCT116 cells MnWwVJJwdGmoZYLheIlwdiCjc4PhfS=> NUDCeYx2PzJiaB?= NWP3T2g5SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBi[nOxcnLhcoNmKGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9OVEvQDJizszNMi=> M2qwPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkmzO|g4Lz5{NU[5N|c5PzxxYU6=
human HL60 cells M{DQfHBzd2yrZnXyZZRqd25iYYPzZZk> MlfKO|IhcA>? NHjLW2lCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjMOlAh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDhZpNwemKjbnPlJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MUiuOFMh|ryPLh?= Mo\wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4OUO3PFcoRjJ3NkmzO|g4RC:jPh?=
Sf9 cells Mn;PSpVv[3Srb36gZZN{[Xl? NWLmeFFXUW6qaXLpeIlwdiCxZjDIbZMufGGpZ3XkJIh2dWGwIFPLNkBmgHC{ZYPz[YQhcW5iU3[5JINmdGy|LDDJR|UxKD1iNj65JO69VS5? NW\yNo9CRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUC5PVg{PTFpPkGwPVk5OzVzPD;hQi=>
HeLa cells NVT0fYpLTnWwY4Tpc44h[XO|YYm= MlvQTY4hfmm2cn:gbY5pcWKrdHnvckBw\iCGTlGt[IVx\W6mZX70JJBzd3SnaX6gb4lv[XOnKFTORU1RUyliZoLvcUBJ\UyjIDjoeY1idiClYYLjbY5wdWFrIHPlcIx{NixiSVO1NEA:KDFwNDFOwG0v NIjJVYw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMkm0NVM{QSd-MUK5OFE{Ozl:L3G+
HeLa cells MWLGeY5kfGmxbjDhd5NigQ>? M4qy[WlvcGmkaYTpc44hd2ZiRF7BJIRmeGWwZHXueEBxem:2ZXnuJItqdmG|ZTDpd49t[XSnZDDmdo9uKEinTHGgZ4VtdHNuIFnDOVAhRSBzLkWg{txONg>? NVXMb5R{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUW2OVg5PzBpPkG1OlU5QDdyPD;hQi=>
Sf21 cells M1\nOWZ2dmO2aX;uJIF{e2G7 MXvJcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KFCLM1vi[ZRiKGW6cILld5Nm\CCrbjDiZYN2dG:4aYL1d{1qdm[nY4Tl[EBU\jJzIHPlcIx{NCCLQ{WwJF0hOC57IN88UU4> NHL0fmI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUe0PFI3QSd-MUm3OFgzPjl:L3G+
Sf21 cells MXnGeY5kfGmxbjDhd5NigQ>? NYfaZZZFUW6qaXLpeIlwdiCxZjDic5ZqdmVicnXjc41jcW6jboSgVGk{U2ejbX3hJIV5eHKnc4Pl[EBqdiCkYXP1cI93cXK3cz3pcoZm[3SnZDDT[lIyKGOnbHzzMEBKSzVyIE2gO{DPxE1w MmnaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl5NEiyOlkoRjF7N{S4NlY6RC:jPh?=
HeLa cells M4XieGZ2dmO2aX;uJIF{e2G7 M3H0PWFkfGm4aYT5JIF1KFCLM1ugbY4hcHWvYX6gTIVN[SClZXzsd{BjgSCHTFnTRUwhTUN3MDC9JFEvPSEQvF2u NHLqboQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEC5NlMzOyd-MkCwPVI{OjN:L3G+
Sf21 cells MnLqSpVv[3Srb36gZZN{[Xl? MoraTY5pcWKrdHnvckBw\iCSSUPL[IVtfGFiZYjwdoV{e2WmIHnuJINmdGy|IHPvMYV5eHKnc4PpcochVi22ZYLtbY5idCCKaYOteIFo\2WmIHj1cYFvKHB6NXGgeZNqdmdiTD3hcJBp[S2yaH;zdIhifGmmeXzpco9{cXSxbDDzeYJ{fHKjdHWgZpkhXEyFIHLhd4VlKHCqb4PwbI9zKGmvYXfpcoctKEmFNUCgQUAxNjV5IN88UU4> NIHwXow9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkWyNFY{OCd-MkK1NlA3OzB:L3G+
Sf21 cells MYLGeY5kfGmxbjDhd5NigQ>? NHT1PW5KdmirYnn0bY9vKG:oIHj1cYFvKHerbHSgeJlx\SCSSUPLZoV1[SCneIDy[ZN{\WRiaX6gV4YzOSClZXzsd{Bkdy2neIDy[ZN{cW6pIF6teIVzdWmwYXygTIl{NXSjZ3fl[EBpfW2jbjDwPFViKHW|aX7nJGwu[WyyaHGtdIhwe3CqYYTp[JltcW6xc3n0c4whe3Wkc4TyZZRmKGK7IGTMR{Bj[XOnZDDwbI9{eGixcjDpcYFocW6pLDDJR|UxKD1iMD65O{DPxE1w NYPzd482RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK1NlA3OzBpPkKyOVIxPjNyPD;hQi=>
HL60 cells NWHT[2xrSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= M2T5[|Mh\GG7cx?= MWTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiONkCgZ4VtdHNibXXhd5Vz\WRiYX\0[ZIhOyCmYYnzJIJ6KE2WUzDhd5NigSxiSVO1NEA:KDF2IN88UU4> NEn4Wo89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nkm0OVEyOCd-Mk[5OFUyOTB:L3G+
U937 cells MVzBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? M4PvZ|Mh\GG7cx?= NVPSWXhLSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDVPVM4KGOnbHzzJI1m[XO3cnXkJIFnfGW{IEOg[IF6eyCkeTDNWHMh[XO|YYmsJGlEPTBiPTCxOEDPxE1w MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjl2NUGxNEc,OjZ7NEWxNVA9N2F-
Jurkat cells Ml;5RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MUezJIRigXN? MljiRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCMdYLrZZQh[2WubIOgcYVie3W{ZXSgZYZ1\XJiMzDkZZl{KGK7IF3UV{Bie3OjeTygTWM2OCB;IEKyJO69VS5? NUX4TIFoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[5OFUyOTBpPkK2PVQ2OTFyPD;hQi=>
K562 cells M1TQOmFvfGmycn;sbYZmemG2aY\lJIF{e2G7 MXWzJIRigXN? MnPXRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCNNU[yJINmdGy|IH3lZZN2emWmIHHmeIVzKDNiZHH5d{BjgSCPVGOgZZN{[XluIFnDOVAhRSB|ODFOwG0v NIPtWG49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nkm0OVEyOCd-Mk[5OFUyOTB:L3G+
U266 cells MontRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? M4DQUVMh\GG7cx?= NIXIc|dCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGWyOlYh[2WubIOgcYVie3W{ZXSgZYZ1\XJiMzDkZZl{KGK7IF3UV{Bie3OjeTygTWM2OCB;IES2JO69VS5? NGrDSZk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nkm0OVEyOCd-Mk[5OFUyOTB:L3G+
MDA-MB-231 cells MlyyRY51cW2rZ4LheI9zgSCjc4PhfS=> NWLzNmhwOjRiaILz M4KyS2FvfGmvaXfyZZRwenliYXP0bZZqfHliYXfhbY5{fCCHR1[gbY5lfWOnZDDjbIVud3SjeHnzJIlvKGi3bXHuJG1FSS2PQj2yN|Eh[2WubIOgdJJmcW6ldXLheIVlKG[xcjCyOEBpenNiZn;scI94\WRiYomgSWdHKGGmZHn0bY9vKG[xcjCzMlUhcHK|IHL5JIxq\2i2IH3pZ5Jwe2OxcImsJGlEPTBiPTCwMlM5KM7:TT6= MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzV7OEKzO{c,Ojd3OUiyN|c9N2F-
MDA-MB-231 cells M1XJVWFvfGmrbo\hd4l3\SCjc4PhfS=> MUizMlUhcHK| NFPmV3FCdnSraX72ZZNqfmViYXP0bZZqfHliaX6gbJVu[W5iTVTBMW1DNTJ|MTDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKEWJRj3pcoR2[2WmIHPlcIwhcW64YYPpc44h[W[2ZYKgN{42KGi{czygTWM2OCB;IECuN|gh|ryPLh?= MoPnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjhyMEm1NlEoRjJ6MEC5OVIyRC:jPh?=
HEK293T cells MUXGeY5kfGmxbjDhd5NigQ>? NFXzTZEyKGi{ NUH1bFFYUW6qaXLpeIlwdiCxZjDpcY1w[mmuaYrl[EBPNUy\Mkm0NFAzKGKnYXSgZolv\GmwZzD0c{BRUTONYnX0ZUApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCKRVuyPVNVKGOnbHzzJIlv[3WkYYTl[EBnd3JiMTDodkBjgSCOQz3NV{9OWyCjbnHsfZNqeyxiSVO1NEA:KDBwNEKg{txONg>? M3nkZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiwNlYyLz5{OEK4NFI3OTxxYU6=
HEK293T cells NF7rVIVHfW6ldHnvckBie3OjeR?= MXOxJIhz NWHJdGY1UW6qaXLpeIlwdiCxZjDpcY1w[mmuaYrl[EBPNUy\Mkm0NFAzKGKnYXSgZolv\GmwZzD0c{BRUTONZHXseIEhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iSFXLNlk{XCClZXzsd{BqdmO3YnH0[YQh\m:{IEGgbJIh[nliTFOtUXMwVVNiYX7hcJl{cXNuIFnDOVAhRSBzLkWzJO69VS5? Mn\hQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OECyOlEoRjJ6MkiwNlYyRC:jPh?=
HEK293T cells NFXGd4ZHfW6ldHnvckBie3OjeR?= MojmNUBpeg>? NHK4NXpKdmirYnn0bY9vKG:oIHntcY9jcWyrenXkJG4uVFl{OUSwNFIh[mWjZDDibY5lcW6pIITvJHBKO0ujbIDoZUApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCKRVuyPVNVKGOnbHzzJIlv[3WkYYTl[EBnd3JiMTDodkBjgSCOQz3NV{9OWyCjbnHsfZNqeyxiSVO1NEA:KDJwM{eg{txONg>? M4q5bVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiwNlYyLz5{OEK4NFI3OTxxYU6=
MDA-MB-231 cells MWTGeY5kfGmxbjDhd5NigQ>? M4DIUGlvcGmkaYTpc44hd2ZiRVfGMYlv\HWlZXSgbY53[XOrb36gc4YhcHWvYX6gUWRCNU2ELUKzNUBk\WyuczDifUBOXFRiYYPzZZktKEmFNUCgQUAxNjN6IN88UU4> MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDNyMkSwNUc,Ojh|MEK0NFE9N2F-
MCF7 cells Mn3jSpVv[3Srb36gZZN{[Xl? NXPNN|NOOTBidV2= NYOzVFhyOSCqch?= NVP2VI5IUW6qaXLpeIlwdiCxZjDJS2YyWiCyaH;zdIhwenmuYYTpc44h[XRiVInyNVE3OSC{ZYPp[JVmKGmwIHj1cYFvKE2FRkegZ4VtdHNiYYSgNVAhfU1iYX\0[ZIhOSCqcjDifUBJd2WlaIP0JFM{OjV6IIP0ZYlvcW6pIHLhd4VlKGmvbYXuc4hqe3SxY3jlcYlk[WxiYX7hcJl{cXN? NUnWc5R{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki1OVc1OzBpPkK4OVU4PDNyPD;hQi=>
SKOV3 cells MVfGeY5kfGmxbjDhd5NigQ>? MlThNlAhfU1? MoW2NlQhcHK| NGP2[nlKdmirYnn0bY9vKG:oIFLEUmYucW6mdXPl[EBqdn[jc3nvckBqdiCqdX3hckBUU0:YMzDj[YxteyCjdDCyNEB2VSCjZoTldkAzPCCqcoOgbY4h[nlibXH0dolo\WxiaX72ZZNqd25iYYPzZZk> M3G4dFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MUKyOFg1Lz5{OUGyNlQ5PDxxYU6=
SKOV3 cells M4HlV2FvfGmvaXfyZZRwenliYYPzZZk> Mli3NlAhfU1? NYHYbHBkOjRiaILz MU\BcpRqdWmpcnH0c5J6KGGldHn2bZR6KGGpYXnud5QhcHWvYX6gV2tQXjNiY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBDTE6ILXnu[JVk\WRiY3XscEBucWe{YYTpc44h[XRiMkCgeW0h[W[2ZYKgNlQhcHK|IHL5JJNkemG2Y3ige492dmRiaHXhcIlv\yCjc4PhfS=> MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTF{MkS4OEc,OjlzMkK0PFQ9N2F-
NB1643 cells Mnu1dWhVWyCjc4PhfS=> M{Tz[ZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQkG2OFMh[2WubIO= M33DPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
OHS-50 cells NVHubnc5eUiWUzDhd5NigQ>? MlHRdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE:KUz21NEBk\Wyucx?= MmfEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
SJ-GBM2 cells NFnYUXNyUFSVIHHzd4F6 NH\VS3VyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1qtS2JOOiClZXzsdy=> MnzuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
SK-N-MC cells MVfxTHRUKGG|c3H5 NIHwS4ZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1OSyClZXzsdy=> M1jiOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
J774 cells M3nCfmFvfGmrbn\sZY1u[XSxcomgZZN{[Xl? MmfmNlQhcHK| NUXkT|g1SW62aXnu[oxidW2jdH;yfUBi[3Srdnn0fUBqdiCvb4Xz[UBLPzd2IHPlcIx{KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDpckBNWFNvaX7keYNm\CCPQ2CxJIV5eHKnc4Ppc44h[W[2ZYKgNlQhcHK|IHL5JGVNUVODLDDJR|UxKD1iMz63JO69VS5? NEPPe5g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUeyOlY5OCd-Mkm3NlY3QDB:L3G+
J774 cells Ml7URY51cWmwZnzhcY1ifG:{eTDhd5NigQ>? MXWyOEBpenN? MlHTRY51cWmwZnzhcY1ifG:{eTDhZ5Rqfmm2eTDpckBud3W|ZTDKO|c1KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDMVHMucW6mdXPl[EBKVDZiZYjwdoV{e2mxbjDh[pRmeiB{NDDodpMh[nliRVzJV2EtKEmFNUCgQUA2NjFizszNMi=> NE\1UXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUeyOlY5OCd-Mkm3NlY3QDB:L3G+
J774 cells MlH5RY51cWmwZnzhcY1ifG:{eTDhd5NigQ>? MViyOEBpenN? NFvPWmNCdnSraX7mcIFudWG2b4L5JIFkfGm4aYT5JIlvKG2xdYPlJGo4PzRiY3XscJMh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJGxRWy2rbnT1Z4VlKG6rdILpZ{BwgGmmZTDwdo9lfWO2aX;uJIFnfGW{IEK0JIhzeyCkeTDHdolme3NiYYPzZZktKEmFNUCgQUA5NjlizszNMi=> NUX1WlVvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3NlY3QDBpPkK5O|I3PjhyPD;hQi=>
J774 cells M4XsNmZ2dmO2aX;uJIF{e2G7 Mn\xNVAhfU1? MY[0JIhzew>? Mny3TY5pcWKrdHnvckBw\iCSSUPLM2FsfCCrbjDtc5V{\SCMN{e0JINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiCOUGOtbY5lfWOnZDDBb5QheGixc4Doc5J6dGG2aX;uJIF1KFOnckS3N{BifCBzMDD1UUBi\nSncjC0JIhzeyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM> MlXCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5Mk[2PFAoRjJ7N{K2OlgxRC:jPh?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
E-cadherin / p-Akt / Akt; 

PubMed: 29731993     


Immunoblot analysis of E-cadherin, P-AKT, and AKT in SNU-C5/5-FU cells treated with LY294002 (20 μM).

beta-catenin / p-GSK3β / Cyclin D1; 

PubMed: 29731993     


Immunoblot analysis of P-AKT, AKT, β-catenin, P-GSK-3β, GSK-3β, and cyclin D1 in SNU-C5/5-FU cells treated with LY294002 (20 μM).

Bcl-xl / Bax / caspase3 / cleaved caspase-3; 

PubMed: 25344912     


Four esophageal cancer cell lines were treated with different concentrations of LY294002 for 48 h, and cell lysates were collected for Western blot analysis of p-AKT, AKT, p-GSK3β, GSK3β, Bcl-xL, Bax, caspase-3, and cleaved caspase-3.

p-p70S6K (T389) / p-GSK3β(S9) / pERK / Vinculin; 

PubMed: 23251002     


HT29, Colo205, and RKO cells were treated for 2 h with PLX4720, LY294002 or their combination at indicated concentrations. Cell lysates were subjected to western blot analysis with antibodies against phosphorylated or total forms of AKT or ERK1/2, and antibodies against p-P70S6K, pGSK3β or vinculin.

pPKB-S473; 

PubMed: 20649566     


Typical Western blot showing that basal pPKB-S473 was reduced by increasing concentrations of LY294002 (upper panel). Pre-incubating 10 µM of the MEK-1/2 inhibitor U0126 induced pPKB–S473 levels which were reduced when rising concentrations of LY294002 were added. A full suppression of pPKB–S473 below the detection limit was seen at 30 µM PI3K inhibitor (10 µM U0126 + 30 µM LY294002). β-Actin immunoreaction served as loading control.

29731993 25344912 23251002 20649566
Growth inhibition assay
Cell viability; 

PubMed: 25344912     


MTT assay was used to determine the effects of different concentrations of LY294002 on viability of esophageal cancer cells lines KYSE150, HKESC-1, KYSE270, and T.Tn. Bars, SD; * P < 0.05; **, P < 0.01; ***, P < 0.001 compared with DMSO-treated cells.

25344912
Immunofluorescence
α-SMA / CD31; 

PubMed: 27671604     


Immunofluorescence analysis for the expression levels of CD31 and α-SMA in Control, LY294002, As2O3 and As2O3 + LY294002 groups. Scale bar = 30 μm. (in HAECs).

E-cadherin / beta-catenin; 

PubMed: 29731993     


The localization of E-cadherin and β-catenin were confirmed by confocal microscopy. Scale bars, 20 μm.

COX-2 / p-NFκB; 

PubMed: 29731993     


The localization of Cox-2 and P-NF-κB was confirmed by confocal microscopy. Scale bars, 20 μm.

FOXO3a; 

PubMed: 18388194     


C2C12 cells were plated into two-well chamber sliders for 24 h and then treated with 20 μm LY294002 or the same amount of vehicle (ethanol) for 16 h. Cells were fixed and FOXO3a was stained. LY294002 treatment activates FOXO3a and leads its translocation into the nucleus.

27671604 29731993 18388194
ELISA
IL-10 / IL-1β / TNFα / IL-6; 

PubMed: 22208359     


Microglial cells were pre-treated with LY294002 for 1 h and then stimulated with LPS (100 ng/ml) or PIC (10 μg/ml) for 16 h. ELISA were performed. All values were normalized to those obtained in cultures stimulated with LPS or PIC without LY294002 (= 1). At least 3 cases were analyzed for each experiment, and statistics were performed using t-test comparing values with vs. without LY294002.

22208359
In vivo LY294002 also results in suppression of tumor growth and induction of apoptosis, especially in the LoVo tumors, and therefore shows remarkable effectiveness in the mouse peritonitis carcinomatosa model. [2] LY294002 significantly inhibits growth and ascites formation of ovarian carcinoma. [3]

Protocol

Kinase Assay:

[4]

- Collapse

kinase assays:

PI3K inhibition by LY294002 is determined in a radiometric assay using purified, recombinant enzymes with 1 μM ATP. The kinase reaction is carried out for 1 hour at room temperature (24oC) and is terminated by addition of PBS. IC50 values are subsequently determined using a sigmoidal dose–response curve fit (variable slope). CK2 and GSK3β (glycogen synthase kinase 3β) inhibition is established by kinase selectivity screening. LY294002 is tested against the Upstate panel of kinases in 10 μM ATP.
Cell Research:

[2]

- Collapse
  • Cell lines: Colon cancer cell lines DLD-1, LoVo, HCT15, and Colo205
  • Concentrations: 0–50 μM
  • Incubation Time: 0–48 hours
  • Method:

    1.0×105 cells (100 μL volume/well) are inoculated into 96-well microtiter plates. LY294002 is added to triplicate wells and cultured at 37oC for 0–48 hours. After treatment, 10 μL of Premix WST-1 are added to each microculture well, and the plates are incubated for 60 minutes at 37oC, after which absorbance at 450 nm is measured with a microplate reader.


    (Only for Reference)
Animal Research:

[3]

- Collapse
  • Animal Models: Two groups of athymic nude mice (5–7 weeks) are inoculated i.p. with OVCAR-3 cells
  • Dosages: 0–100 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 36 mg/mL (117.13 mM)
Ethanol 21 mg/mL (68.32 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+ 40%PEG 300+5% Tween 80+50%ddH2O
For best results, use promptly after mixing.
3mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 307.34
Formula

C19H17NO3

CAS No. 154447-36-6
Storage powder
in solvent
Synonyms SF 1101, NSC 697286
Smiles C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=CC=C4

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I want to buy a inhibitor that can inactivates Akt/PI3K. I notice the protocol of LY294002 (catalog no. s1105) says it will inactivates Akt/PKB. Is LY294002 available for Akt/PI3K inhibition?

  • Answer:

    LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively. It can inhibit PI3K/AKT. PKB is the alternative name of AKT.

  • Question 2:

    What is the suggested formulation of this compound for mouse injection(i.p.)?

  • Answer:

    It can be dissolved in 4% DMSO/30% PEG 300/5% Tween 80/ddH2O at 5 mg/ml clearly, and the concentration of DMSO is safe for in vivo experiments.

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Tags: buy LY294002 | LY294002 supplier | purchase LY294002 | LY294002 cost | LY294002 manufacturer | order LY294002 | LY294002 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID